November 14, 2017
October 13, 2017
September 07, 2017
September 06, 2017
CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM.
CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.
CASI's turnaround turns eastward; firm seeks to be Celgene of China
Rodman & Renshaw 19th Annual Global Investment Conference
Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret Phase 2 consortium